Tyenne Shortage: What Providers and Prescribers Need to Know in 2026

Tyenne (tocilizumab-aazg), the first tocilizumab biosimilar approved for both intravenous and subcutaneous use in the United States, has been commercially available since April 2024 (IV) and July 2024 (SC). As this biosimilar becomes more embedded in rheumatology practice, providers need current information on availability, formulary positioning, prior authorization requirements, and patient support options.

This article is intended for rheumatologists, primary care providers, pediatric rheumatologists, and advanced practice providers who prescribe or manage patients on tocilizumab therapy.

Tyenne Availability Status in 2026

As of 2026, Tyenne is NOT listed on the FDA Drug Shortage database and is commercially available through specialty pharmacy channels and for IV infusion administration in clinical settings. The supply situation for Tyenne is stable.

Provider-reported access difficulties for Tyenne are almost universally administrative in nature — prior authorization delays, step therapy requirements, or specialty pharmacy routing — rather than product supply issues. Prescribers who understand these administrative requirements can help patients navigate them more efficiently.

The Tocilizumab Biosimilar Landscape in 2026

As of 2026, there are three FDA-approved tocilizumab biosimilars in the U.S. market:

Tyenne (tocilizumab-aazg) — Fresenius Kabi: IV and SC. FDA approved March 5, 2024. IV launched April 2024, SC launched July 2024. First tocilizumab biosimilar to launch in the U.S. market.

Tofidence (tocilizumab-bavi) — Biogen/Bio-Thera: IV only. FDA approved September 2023, launched May 2024.

Avtozma (tocilizumab-anoh) — Celltrion: IV and SC. FDA approved January 2025, launched October 2025.

Tyenne is currently positioned as the preferred tocilizumab biosimilar on multiple major payer formularies. When writing biosimilar tocilizumab prescriptions, using "tocilizumab biosimilar" with Tyenne as the brand of record — or writing directly for Tyenne — will align with preferred formulary status on many plans and reduce PA turnaround time.

Key Clinical Differences: Tyenne vs. Actemra

Tyenne is biosimilar to Actemra with no clinically meaningful differences in safety, purity, or potency. However, prescribers should be aware of one important distinction:

Indication gap: Actemra is also approved for systemic sclerosis-associated interstitial lung disease (SSc-ILD). Tyenne does NOT carry this indication. For patients with SSc-ILD specifically, Actemra may remain the appropriate prescribing choice.

No interchangeability designation: Tyenne has not received an interchangeability designation from the FDA. Pharmacist-level substitution of Tyenne for Actemra (or vice versa) without prescriber consent is not permitted in all states — a new prescription is typically needed.

Prior Authorization Requirements: What to Prepare

Most commercial insurance plans require prior authorization for Tyenne. Common documentation requirements include:

Confirmed diagnosis (RA, GCA, PJIA, SJIA, CRS, or COVID-19)

Disease Activity Score (DAS28) or clinical notes documenting moderate-to-severe activity

Documentation of prior DMARD therapy and inadequate response (step therapy evidence)

Baseline labs: CBC, LFTs (ALT/AST), lipid panel, TB screening (prior to initiation)

Letter of medical necessity if step therapy exceptions are needed

Having this documentation ready at the time of PA submission significantly reduces turnaround time. Many plans are approving Tyenne within 5–10 business days when documentation is complete on first submission.

Managing Patients Transitioning From Actemra to Tyenne

As more payers prefer Tyenne over Actemra on formulary, prescribers may face requests to transition established Actemra patients to Tyenne. Here's guidance for managing this:

Transitions should be done with a new prescription — not a pharmacist substitution

Same dosing and schedule applies; no dose adjustment required for biosimilar switch

Educate patients that clinical outcomes should be equivalent — clinical studies show biosimilarity in efficacy, safety, and immunogenicity

Patients transitioning from SC Actemra to SC Tyenne should receive training on the Tyenne autoinjector/prefilled syringe (KabiCare provides this)

KabiCare: Provider-Facing Resources

Fresenius Kabi's KabiCare program offers hub support for prescribers including:

Benefits investigation and PA submission assistance

Appeals support for denied PA requests

Specialty pharmacy coordination and routing

Patient copay assistance enrollment (commercially insured patients may reduce costs to $0)

For providers looking for broader medication access support for their patient panel, medfinder for providers offers a service that contacts pharmacies on behalf of your patients to locate medications in stock — reducing the administrative burden on your office staff.

For patient-facing information on Tyenne availability, see our Tyenne shortage update for patients.